Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Clinical Significance of Cellular Immune Adjuvant Therapy of Triple Negative Breast Cancer

NCT02539017 is registered in ClinicalTrials.gov with First Affiliated Hospital Xi'an Jiaotong University as lead sponsor.

NCT NCT02539017
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02539017 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Clinical Significance of Cellular Immune Adjuvant Therapy of Triple Negative Breast Cancer
Lead sponsor
First Affiliated Hospital Xi'an Jiaotong University
Phase
Phase 2
Overall status
Withdrawn
Start date
November 30, 2015
Completion date
Not reported
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

triple negative breast neoplasms